全文获取类型
收费全文 | 504篇 |
免费 | 41篇 |
出版年
2023年 | 3篇 |
2022年 | 7篇 |
2021年 | 12篇 |
2020年 | 10篇 |
2019年 | 7篇 |
2018年 | 17篇 |
2017年 | 13篇 |
2016年 | 14篇 |
2015年 | 26篇 |
2014年 | 31篇 |
2013年 | 38篇 |
2012年 | 47篇 |
2011年 | 39篇 |
2010年 | 25篇 |
2009年 | 18篇 |
2008年 | 20篇 |
2007年 | 26篇 |
2006年 | 19篇 |
2005年 | 10篇 |
2004年 | 16篇 |
2003年 | 16篇 |
2002年 | 10篇 |
2001年 | 7篇 |
2000年 | 7篇 |
1999年 | 5篇 |
1998年 | 2篇 |
1997年 | 2篇 |
1996年 | 2篇 |
1993年 | 7篇 |
1992年 | 6篇 |
1991年 | 2篇 |
1990年 | 10篇 |
1989年 | 2篇 |
1988年 | 2篇 |
1987年 | 2篇 |
1986年 | 3篇 |
1984年 | 3篇 |
1983年 | 3篇 |
1981年 | 6篇 |
1980年 | 3篇 |
1979年 | 7篇 |
1978年 | 6篇 |
1977年 | 5篇 |
1976年 | 4篇 |
1974年 | 4篇 |
1972年 | 6篇 |
1968年 | 3篇 |
1967年 | 2篇 |
1961年 | 2篇 |
1959年 | 1篇 |
排序方式: 共有545条查询结果,搜索用时 15 毫秒
541.
Saskia van Henten Annisa Befekadu Tesfaye Seid Getahun Abdela Feleke Tilahun Helina Fikre Jozefien Buyze Mekibib Kassa Lieselotte Cnops Myrthe Pareyn Rezika Mohammed Florian Vogt Ermias Diro Johan van Griensven 《PLoS neglected tropical diseases》2021,15(5)
BackgroundCutaneous leishmaniasis (CL) in Ethiopia, caused by Leishmania aethiopica, is often severe and hard to treat compared to CL caused by other species elsewhere. Miltefosine is the only oral anti-leishmanial drug, with a favorable side-effect profile compared to routinely available sodium stibogluconate (SSG), but evidence about its use for L. aethiopica is lacking.Methodology and principal findingsIn an observational cohort study, treatment outcomes, safety and adherence among CL patients who required systemic treatment and received miltefosine for 28 days in Boru Meda Hospital and University of Gondar Hospital were studied. Patient cure was defined as 100% flattening for non-ulcerated lesions and 100% flattening and 100% re-epithelization for ulcerated lesions. Outcomes were documented for day 28, 90 and 180, both per site, and pooled, adjusting for site as a fixed effect with effect coding. Among 94 included patients (32 in Gondar, 62 in Boru Meda), median lesion duration was 12 months, median size six cm, and mucosal involvement (46.8%) and diffuse (30.9%) lesions were common. Adherence to miltefosine was good, and side-effects were tolerable. Initial outcomes at day 28 were promising, with 68.8% and 94.0% of patients having good improvement or cure in Gondar and Boru Meda respectively. In Boru Meda, outcomes were good with 72.7% and 72.9% cure at day 90 and day 180 respectively. In Gondar, results were less promising, with only 12.5% and 26.7% cure at day 90 and day 180, although confidence intervals were wide. In pooled estimates, 48.7% of patients reached cure at day 180, and 32.3% relapsed. Outcomes were better in Boru Meda Hospital, for smaller lesions and for mucosal lesions.Conclusions/SignificanceBased on miltefosine’s good initial response, tolerable side-effects, tablet-form, we propose to include miltefosine for future clinical trials using extended treatment schedules, combination therapy, or targeting specific subgroups.Trial registrationClinicalTrials.gov . NCT04004754相似文献
542.
Deoxyribonucleic acid in amphibian eggs 总被引:32,自引:0,他引:32
I B Dawid 《Journal of molecular biology》1965,12(3):581-599
543.
Sungwoon Choi Alyssa N. Calder Eliza H. Miller Kierstyn P. Anderson Dawid K. Fiejtek Anne Rietz Hongxia Li Jonathan J. Cherry Kevin M. Quist Xuechao Xing Marcie A. Glicksman Gregory D. Cuny Christian L. Lorson Elliot A. Androphy Kevin J. Hodgetts 《Bioorganic & medicinal chemistry letters》2017,27(23):5144-5148
Spinal muscular atrophy (SMA) is a neurodegenerative disorder that results from mutations in the SMN1 gene, leading to survival motor neuron (SMN) protein deficiency. One therapeutic strategy for SMA is to identify compounds that enhance the expression of the SMN2 gene, which normally only is a minor contributor to functional SMN protein production, but which is unaffected in SMA. A recent high-throughput screening campaign identified a 3,4-dihydro-4-phenyl-2(1H)-quinolinone derivative (2) that increases the expression of SMN2 by 2-fold with an EC50?=?8.3?µM. A structure-activity relationship (SAR) study revealed that the array of tolerated substituents, on either the benzo portion of the quinolinone or the 4-phenyl, was very narrow. However, the lactam ring of the quinolinone was more amenable to modifications. For example, the quinazolinone (9a) and the benzoxazepin-2(3H)-one (19) demonstrated improved potency and efficacy for increase in SMN2 expression as compared to 2. 相似文献
544.
545.